Reduced ABO blood group antibody titers in patients after CD19 CAR-T cell therapy  

作　　者：Qiang Li Zhihuan Yang Kuo Fang Shuning Wei Jiali Sun Wei Liu Xiaojuan Chen Wenyang Huang Guangji Zhang Yin Shi Yuntao Liu Xiaoyuan Gong Fang Liu Xueli Zhou Jianxiang Wang Ying Wang 

机构地区：[1]State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Tianjin Key Laboratory of Cell Therapy for Blood Diseases,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China

出　　处：《Blood Science》2023年第1期62-65,共4页血液科学（英文）

基　　金：the CAMS Innovation Fund for Medical Sciences(Grant no.2021-1-I2M-041);Tianjin Municipal Science and Technology Commission Grant(Grant no.20JCZDJC00120).

摘　　要：1.INTRODUCTION With rapid developments in genetic engineering,tumor immunology,and cellular engineering,chimeric antigen receptor T cell(CAR-T)cell therapy has become a novel immunotherapy for oncology and other medical fields.1 The promising results of CD19 CAR-T treating B-cell malignancies were reported.2,3 Simultaneously,there existed many adverse events,the most reported of which including B-cell aplasia,hematological toxicity,cytokine release syndrome(CRS),and immune effector-cell–associated neurotoxicity syndrome(ICANS),3,4 but there is still lack of reports demonstrating the impact of CD19 CAR-T on the ABO blood group potency of patient’s serum.

关 键 词：ABO CD19 CAR 

分 类 号：R733[医药卫生—肿瘤]